Life Science REIT Past Earnings Performance
Past criteria checks 0/6
Life Science REIT's earnings have been declining at an average annual rate of -37.2%, while the Health Care REITs industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 4.3% per year.
Key information
-37.2%
Earnings growth rate
-37.2%
EPS growth rate
Health Care REITs Industry Growth | 11.2% |
Revenue growth rate | 4.3% |
Return on equity | -15.0% |
Net Margin | -199.0% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Life Science REIT makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 20 | -40 | 5 | 0 |
31 Mar 24 | 20 | -31 | 5 | 0 |
31 Dec 23 | 20 | -22 | 5 | 0 |
30 Sep 23 | 20 | -25 | 5 | 0 |
30 Jun 23 | 19 | -29 | 5 | 0 |
31 Mar 23 | 18 | -28 | 6 | 0 |
31 Dec 22 | 16 | -28 | 6 | 0 |
31 Dec 21 | 1 | 19 | 2 | 0 |
Quality Earnings: JL6 is currently unprofitable.
Growing Profit Margin: JL6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if JL6's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare JL6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JL6 is unprofitable, making it difficult to compare its past year earnings growth to the Health Care REITs industry (29.2%).
Return on Equity
High ROE: JL6 has a negative Return on Equity (-14.98%), as it is currently unprofitable.